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Volume 54, Number 6 Abstracts 1853ing to the Denver grading scale were; grades 124%, 235%, 34%,
435%, and 52%. Distribution across segments included; V118%,
V267%, V331%, and V46%. Only one posterior circulation stroke was
attributable to VAI. Overall mortality was 8% being associated with other
injuries. Treatment rendered was antiplatelet therapy (50%), observation
(29%), warfarin (17%) or stent (4%). Follow-up was obtained with 13% (n
6) of survivors. CT angiogram or MRA demonstrated injury stability in 4
patients and resolution in 2 patients. Accuracy of the administrative trauma
database was 53% compared with 96% for the resident-runworking database.
Conclusions:Neurologic sequelae attributable to VAI was rare. Grade
of VAI or vertebral artery segment did not correlate with morbidity. Poste-
rior circulation stroke was low. Patient morbidity and mortality was attrib-
utable to severe associated injuries. Of those seen at follow-up, injury
resolution or stability was documented by CT angiogram. A conservative
approach with either observation or anti-thrombotic therapy is suggested.
Our search strategy urges awareness of the limitations of administrative
databases for retrospective vascular study.
Carotid Endarterectomy is More Cost-Effective Than Carotid Artery
Stenting
W C Sternbergh, III, Gregory D. Crenshaw, Taylor A. Smith,
Hernan A. Bazan, Ochsner Clinic Foundation, New Orleans, La
Background: In a clinical environment where there may be emerging
clinical equipoise between two therapies, the cost of delivering that intervention
becomes increasingly important. Carotid Endarterectomy (CEA) and carotid
artery stenting (CAS) have both demonstrated a reduction in long-term stroke
risk after successful intervention. While the CREST trial demonstrated no
significant differences between CAS and CEA regarding the peri-operative risk
when the primary endpoint of CVA, death orMIwas examined, ameta-analysis
of European randomized prospective trials in symptomatic patients strongly
favored CEA as the safer procedure. In the United States, the percentage of
gross domestic product (GDP) devoted to medical care continues to rise at a
rate that is unsustainable. Going forward, more efficient use of health care
dollars will be essential. Preferential use of the most cost-effective therapy for a
given clinical problem should be part of the solution. In an effort to further
compare treatment of carotid disease, we analyzed hospital cost and clinical
outcome data of patients undergoing CEA and CAS.
Methods: A retrospective analysis of hospital cost and 30-day out-
comes was performed on patients undergoing CEA and CAS between
1/1/2008 and 9/30/2010 at a single tertiary referral institution. The
hospital patient database was queried using CPT codes to search for those
patients who had either undergone CEA (CPT 35301) or CAS with embolic
protection (CPT 37215) during the specified period.
Clinical Definitions: Patients were considered to be symptomatic
from their carotid disease if they had experienced ipsilateral amarousis fugax,
transient ischemic attack (TIA) or stroke. Urgent interventions were defined
as those patients admitted with an acute cerebral or ocular ischemic episode
who were found to have significant ipsilateral carotid disease and underwent
intervention during the index hospitalization. The 30-day clinical major
adverse event was defined as a composite of any stroke, death and MI.
Cost Calculation: The institution’s financial department performed an
analysis of hospital cost (not charges) on the main patient cohorts and sub-
groups detailed above. Professional fees were not included in this analysis. The
cost of the procedure was based on a cost accounting method using the relative
value unit (RVU) system.Eachprocedure or itemcharged to a casewas assigned
an RVU. Costs were then calculated based on the relative RVU valuation. The
cost items were assigned to the following cost centers: labor expense, supply
expense, facility/equipment expense, and miscellaneous. Once the total ex-
pense for the index hospitalization was calculated, it was normalized to 2010
costs based on the medical consumer price index. Statistical analysis was per-
formed with Wilcox’s analysis, X2, and Fisher’s exact test.
Results: Three hundred and fifteen patients underwent either CEA
(n  174) or CAS (n  141) between 1/1/2008 and 9/30/2010. Nine
patients were excluded from the primary cohort (all receiving CAS) because
they had other associated procedures during the index hospitalization which
would have biased the economic analysis. Thus, the final examined cohort
was 306 patients who underwent CEA (n  174) or CAS (n  132).
Demographics: There was a strong trend towards more symptomatic
patients in the CEA cohort (44%, n 78) compared to the CAS group (34%
n  45) which did not attain statistical significance (P  .058). The
frequency of urgent intervention was similar between groups [CEA 12.6%
(n  22) vs CAS 10.0% (n  14); P  .72). The mean age in the CEA and
CAS groups was 70.1 9.8 yrs. and 72.0 9.7 yrs, respectively (P .36).
There was a trend towards a higher prevalence of medical co-morbidities in
the CAS cohort compared to the CEA cohort (94.5% vs 88.9%, respectively;
P  .07), with a higher prevalence of CAD (61% vs 37%, P  ,0001) and
CHF (18.2 vs 5.2%, P  .0003) in the CAS cohort.
Hospital Cost: The hospital cost for CAS ($9426  5776) was 40%
greater than that ofCEA ($67343935,P .0001). This cost differential was
driven by a mean difference of $3667 in higher direct supply costs in the CAS
group ($5634  3384) compared to the CEA group ($1967  1967, P 
.0001). There were no significant differences betweenCEA andCAS in regards
to labor or facility costs (Fig 1). Subgroup analysis was performed comparing
the cost of CEA and CAS for asymptomatic, symptomatic, elective, and urgentrocedures (Fig 2). In all sub-group cohort comparisons, there was a consistent
ncrease in cost for CAS compared to CEA. All of these differences were
tatistically significant (P .001) except the urgent subgroup (P .07).Cost of
AS and CEA was also examined in relation to patient enrollment in a trial or
egistry. Patients undergoing CAS who were enrolled in a trial or registry
53.8%, n  71) incurred significantly less cost ($7779  3525) compared to
hose who were not (n  61, $11,279  7114, P  .0004). There were no
ignificant differences in cost for patients undergoingCEA regarding trial status.
Clinical Outcome: The 30-day major adverse event rate (stroke,
eath, MI) was 2.3% in the CEA group and 3.8% in the CAS group (P .5).
Length of Stay: Overall LOS was 2.1 days in both CEA and CAS
roups (P .9). LOS in patients with symptomatic disease (2.9-3.6 days) or
ho had urgent intervention (7.3-7.5 days) was much greater than patients
ndergoing intervention electively or for asymptomatic disease (1.3-1.4
ays). The LOS between CEA and CAS was similar in all these subgroups.
Conclusions: The hospital cost of CAS was demonstrated to be 40%
reater than CEA. The cost differential in the present study was driven
argely by the significant differential in direct supply costs in the CAS group
f $3667. Current hospital costs for a carotid stent and embolic protection
evice is approximately $3750 - 4100 compared to $90-100 for a synthetic
arotid patch used with endarterectomy. Clearly, the cost differential of
hese two therapies was due to the relatively high cost of the interventional
roducts required for CAS. There was no net significant offsetting savings in
acility or labors costs for the CAS patients as the length of stay was similar
etween the two treatment groups. This is the first carotid economic study
o examine multiple treatment subgroups. Patients with urgent intervention
ncurred costs much greater in both groups than those who where treated
lectively. This cost differential was driven by the much greater LOS for
rgent cases (7.3-7.5 days) compared with elective cases (1.3-1.4 days).
dditional cost for diagnostic imaging in these cases also likely contributed.
atients being treated for symptomatic disease likewise had greater costs
han those treated for asymptomatic disease. Increased LOS in the symp-
omatic groups (2.9-3.6 days) verses the asymptomatic group (1.3-1.4 days)
ertainly played a role. The relative cost trends between CAS and CEA seen
n the primary cohorts were not altered in any subgroup. CAS was consis-
ently more costly in each subgroup. A novel finding of this study was that
AS patients enrolled in a trial or registry had costs that were significantly
ess than those who were treated with CAS outside of a trial. These data refute
he notion that the differential in cost between CEA and CAS is due, in part, to
dditional costs associated with protocol-mandated imaging and testing for
atients enrolled in a trial or registry. The present study represents a “realworld”
ost analysis of CEA and CAS performed at a single, tertiary referral center with
ignificant expertise and experience in both therapies. As such, it may provide a
ore realistic view of costs compared to data generated from clinical trials.
hile a small number of patients were part of randomized prospective trials
CREST, ACT-1), most treatment decisions were made by the intervening
hysician. Selection bias is a clear concern and could confound attempts to
ompare the treatment groups. In an attempt to decrease this possibility, we
xcluded patients who had other major procedures during the index hospital-
zation, or who were not admitted primarily because of TIA, stroke or carotid
isease. Did the treatment groups have disparate demographics or clinical
resentation? Patients undergoing CEA were more likely to have symptomatic
isease when compared to those undergoing CAS. As symptomatic status is a
ery strong risk factor for peri-procedural stroke, this difference would suggest
hat theCEAgroupwas at higher risk of a poor outcome, potentially biasing the
esults against CEA. Conversely, in the CAS group there was a higher preva-
ence of CAD and CHF, suggesting that group had a higher potential cardiac
orbidity, potentially biasing the results against CAS. Patient age and other
edical co-morbidities were similar between treatment groups. In conclusion,
AS was associated with a 40% cost premiumwhen compared to CEA, and did
ot provide any improvement in clinical outcome or LOS. All subgroups had
imilar cost trends. Given the lack of clinical improvement and its cost premium,
AS cannot be considered routinely cost-effective for the treatment of carotid
rtery disease.Fig 1.
C
e
s
c
C
s
w
t
t
d
w
C
a
a
1
s
3
C
e
f
(
t
C
g
o
t
E
r
S
H
M
s
n
C
t
3
p
r
w
p
(
D
i
l
c
t
(
C
(
f
s
a
C
.
y
a
C
d
R
T
R
S
i
3
t
JOURNAL OF VASCULAR SURGERY
December 20111854 AbstractsCerebral Embolization in Asymptomatic vs Symptomatic Patients Af-
ter Carotid Stenting
Hans Tulip, David E. Timaran, Eric B. Rosero, Adriana J. Higuera,
R. James Valentine, Carlos H. Timaran University of Texas Southwestern
Med Ctr, Dallas, Tex
Background: Previous studies have investigated the development of
new ischemic brain lesions on diffusion-weighted MRI (DW-MRI) after
carotid artery stenting (CAS) for symptomatic stenosis. The rate of ischemic
brain injury after CAS for asymptomatic stenosis has not been established,
but is presumed to be less likely. This study assessed the occurrence of
cerebral embolization after CAS for asymptomatic vs symptomatic carotid
stenosis.
Methods: During an 18-month period, 40 patients undergoing CAS
under filter embolic protection were prospectively evaluated. Transcranial
Doppler (TCD) during CAS and pre- and 24-hour postprocedural DW-
MRI were used to assess cerebral embolization. Univariate and nonparamet-
ric analyses were used to compare differences in cerebral embolization after
CAS in asymptomatic and symptomatic patients.
Results: CAS was performed for 23 (58%) asymptomatic and 17
(42%) symptomatic carotid stenoses. The median microembolic counts
detected by TCD were 285 (interquartile range [IQR], 182-376) for
asymptomatic and 313 (IQR, 170-426) for symptomatic carotid stenosis
(P.6). New acute cerebral emboli detected with DW-MRI occurred in
50% of asymptomatic and 50% of symptomatic patients undergoing CAS
(P  .9). The ipsilateral and total median number of DW-MRI lesions
between groups were not statistically significantly different, i.e. 1 (IQR,
0-2.5) and 1.5 (IQR, 0-3) vs 0.5 (IQR, 0-2) and 0.5 (IQR, 0-3) for
asymptomatic vs symptomatic carotid stenosis, respectively (P .5). One
asymptomatic patient sustained a minor stroke after CAS, whereas no
new neurologic events occurred in symptomatic patients; the 30-day
stroke-death rate was 2.5% in this series.
Conclusions: Cerebral embolization, as detected by TCD and DW-
MRI, occurs with similar frequency after CAS for asymptomatic and
symptomatic carotid stenosis. This observational study questions the
safety of CAS under embolic protection for asymptomatic carotid steno-
sis as new ischemic brain injury occurs in approximately half of these
procedures.
Contralateral Occlusion is not a Clinically Important Reason for
Choosing Carotid Artery Stenting for Patients with Significant Carotid
Artery Stenosis
Luke P. Brewster, Karthik P. Kasirajan, Robert Beaulieu, James P. Reeves,
Matthew A. Corriere, Ravi Rajani, Ravi K. Veeraswamy, Atef K. Salam,
Thomas F. Dodson, Joseph J. Ricotta, Emory University Hospital, Atlanta, Ga
Introduction: Patients with internal carotid artery occlusion contralat-
eral to a diseased carotid artery are at an increased risk of stroke. It is our
practice to offer carotid intervention to symptomatic patients and patients
with severe ipsilateral carotid stenosis and contralateral occlusion. Both carotid
endarterectomy (CEA) and carotid artery stenting (CAS) are acceptable modes
of therapy. Contralateral carotid occlusion has been suggested as an indication
for CAS because of the theoretical advantages of reduced ischemic procedural
time and the lack of need for a vascular shunt or the assistance of general
anesthesia. However, CEA can also be done safely in this population and has
Fig 2.been associated with a decreased procedural stroke rate. Thus, it is not clear if
contralateral occlusion by itself is an appropriate indication to prefer CAS over
a
(EA. Here we compare our institution’s perioperative and one-year follow up
xperience with both CEA and CAS for patients with severe carotid artery
tenosis and contralateral internal carotid artery occlusion.
Methods: This is a retrospective review of our institution’s collective
onsecutive patient experience with CAS and CEA from 2/2007-7/2011.
hoice of therapy was determined by operator preference among vascular
urgery, cardiology, and interventional radiology, and the data collection
as performed using our computerized patient record after approval from
he Institutional Review Board. Patients were considered for review when
reated for carotid artery stenosis with contralateral carotid occlusion.
Results:Out of a total of 713 patients treated for carotid artery stenosis
uring this time period, 60 had contralateral occlusion. 40 of these patients
ere treated with CAS, and 20 with CEA. The most common indication for
AS were prior neck surgery (18), contralateral carotid occlusion alone (9),
nd prior neck radiation (7). The average age was 69.8 (/ 8.1) for CEA
nd 67.2 (/8.7) for CAS. There was a male bias in both groups (CEA
3/20; CAS 29/40; P.56), and both groups had similar amount of
ymptomatic patients (CEA 10/20, CAS 19/40). Two patients died within
0 days in the CAS group (5%) and no deaths occurred within 30 days in the
EA group. No perioperative strokes or myocardial infarction occurred in
ither group. One transient ischemic attack occurred after CAS. At mean
ollow up of 28/ 16 months (CEA) and 28/15 months (CAS)
range 1.5-48.5 months), 7 deaths occurred in the CAS group and two in
he CEA group (17.5% vs 10%, P  .7). There were no reoperations in the
EA group and one intervention in the CAS group for in-stent stenosis.
Conclusion: Although CEA and CAS can both be performed with
ood perioperative and midterm results, we find no reason to prefer CEA
ver CAS in patients whose only reason for consideration of CAS is con-
ralateral occlusion.
arly Versus Delayed Carotid Endarterectomy for Symptomatic Ca-
otid Stenosis: A Single-Institution Experience
uman Annambhotla, Michael S. Park, Mark L. Keldahl, Mark D. Morasch,
eron E. Rodriguez, William H. Pearce, Melina R. Kibbe,
ark K. Eskandari, Northwestern University, Chicago, Ill
Introduction: Delayed carotid endarterectomy (CEA) after a recent
troke or transient ischemic attack (TIA) is associated with risks of recurrent
eurologic symptoms. In an effort to preserve cerebral function, urgent early
EA has been recommended in some instances.
Methods: Retrospective chart review from a single university hospital
ertiary care center between November 1998 and February 2011 revealed
09 patients who underwent CEA following stroke or TIA. Of these 309
atients, 87 received their CEA within 30 days of symptom onset and 222
eceived their CEA after 30 days from symptomonset. The early CEA cohort
as further stratified according to the timing of surgery: Group A (33
atients), within 7 days; Group B (21), between 8 and 14 days; Group C
17), between 15 and 21 days; and Group D (15), between 22 and 30 days.
emographic data as well as 30-day (mortality, stroke, TIA, and myocardial
nfarction) and long-term (all-cause mortality and stroke) rates were ana-
yzed for each Group. These were also analyzed for the entire early CEA
ohort and compared against the delayed CEA cohort.
Results: Demographics and co-morbid conditions were similar be-
ween groups. For 30-day outcomes, there were no deaths (0%), two strokes
2.4%), two TIAs (2.4%), and two myocardial infarctions (2.4%) in the early
EA cohort; in the delayed CEA cohort, there were 4 (1.8%), 4 (1.8%), 3
1.4%), and 3 (1.4%) patients with these outcomes, respectively (P  0.05
or all comparisons). Over the long-term, the early group had one ipsilateral
troke at 17 months and the delayed group had two ipsilateral strokes at 3
nd 12 months. For long-term outcomes, there were 21 deaths in the early
EA cohort (24.4%) and 67 deaths in the delayed CEA cohort (30.2%, P
05). Mean follow-up times were 4.5 years in the early CEA cohort and 5.8
ears in the delayed CEA cohort.
Conclusions: There were no differences in 30-day and long-term
dverse outcome rates between the early and delayed CEA cohorts. Early
EA is preferred in carefully selected patients following a TIA or non-
isabling stroke over delayed CEA.
obotic Thoracoscopic First Rib Resection and Scalenectomy for
reatment of Pagett-Schroetter Syndrome
ichard F. Neville1, Farid Gharagozloo2,MarkMeyer3, Barbara Tempesta2,
rini Tummala4 1George Washington University, Washington, DC; 2Wash-
ngton Institute of Thoracic and Cardiovascular Surgery, Washington, DC;
Institute of Thoracic and Cardiovascular Surgery, Washington, DC; 4Res-
on Radiology Consultants, Reston Hospital, Reston, Va
Objectives: First rib resection is a key component of the treatment for
xillo-subclavian venous thrombosis due to thoracic outlet compression
Paget-Schroetter syndrome). Previously described techniques, transaxillary
